Market Trends of Nucleic Acid Amplification Testing (NAAT) Industry
This section covers the major market trends shaping the Nucleic Acid Amplification Testing Market according to our research experts:
The Infectious Disease Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi. The diseases can spread, directly or indirectly, from one person to another. The common infectious diseases are strep throat and urinary tract infections (caused by bacteria), HIV/AIDS, the common cold (caused by a virus), influenza, STIs, tuberculosis, and athlete's foot (common fungus), among others.
According to the World Health Organization in August 2022, sexually transmitted infections (STIs) have a significant impact on sexual and reproductive health worldwide and over 1 million STIs are acquired every day in the world. Furthermore, according to the same source, 374 million new infections are estimated with STIs such as chlamydia, gonorrhea, syphilis, and trichomoniasis every year in the world. Thus, such a high incidence of infectious diseases is expected to increase the demand for NAAT testing, driving the market growth over the forecast period.
Furthermore, according to the study published in Infectious Medicine in March 2022, the NAAT has higher sensitivity in the detection of tuberculosis compared to other diagnostic tests such as smear and culture tests. The high sensitivity of this test in the detection of infectious diseases such as tuberculosis is expected to drive segment growth due to its increased adoption in tuberculosis testing.
Thus, the rising prevalence of various infectious diseases and the rising importance of NAAT in the diagnosis of infectious diseases is expected to boost the segment's growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The North American region is expected to dominate the global market owing to the presence of better healthcare infrastructure, the presence of prominent market players, and the rising prevalence of infectious and chronic diseases.
For instance, according to the ACS Cancer Facts & Figures 2022, around 1,918,030 new cancer cases are estimated to be reported in the United States in the year 2022. Furthermore, according to Statistics Canada in June 2022, it is estimated that around 233,900 people in Canada will be diagnosed with cancer in 2022. The huge cancer burden is increasing the need for diagnostic tests like NAAT driving the market growth in the region.
Additionally, a few of the key market players in the country are developing advanced diagnostics kits to compete with the existing products, while others are acquiring and partnering with the other companies trending in the market. For instance, in September 2022, BD and CerTest Biotec developed a molecular polymerase chain reaction (PCR) assay for the monkeypox virus. Such developments are further bolstering the market growth in the region due to the increased adoption of NAAT testing.
Furthermore, in November 2022, Pulse Scientific was named the national distributor in Canada for Covid-19 & Flu at-home molecular tests developed by Lucira Health. The Lucira testing platform is a Nucleic Acid Amplification Test (NAAT) with sensitivity and specificity comparable to lab-based PCR assays. Therefore, the rising distribution of NAAT in Canada is expected to drive market growth in the region due to the rise in adoption by people for testing infectious diseases conveniently at home.
Thus, the above-mentioned factors such as the rising prevalence of cancers, and rising initiatives from the key market players in launching their products are expected to witness high growth.
